---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126734"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:30:11.247485+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics Q3 net loss $6.1M; FDA approved ORLYNVAH in October 2024

## Summary
- Cash, cash equivalents and short-term investments totaled $14.5M at Sept. 30, 2024.
- FDA approved ORLYNVAH for uUTI on Oct. 25, 2024; 10 years of GAIN Act exclusivity.
- Net loss Q3 2024 was $6.1M vs $3.9M in Q3 2023; non-GAAP net loss $4.8M vs $15.7M.
- R&D expenses fell to $3.1M from $14.9M due to completion of REASSURE trial enrollment.
- Company seeking strategic partners for ORLYNVAH; cash expected to fund into 2025.

## SEC filing metadata
- accession: 0000950170-24-126734
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017024126734/0000950170-24-126734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017024126734/itrm-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126734
- JSON: https://secwatch.observer/filing/0000950170-24-126734.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126734.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.